| scholarly article | Q13442814 |
| P50 | author | Judith Knievel | Q63968650 |
| Annemarie Greife | Q93105553 | ||
| Günter Niegisch | Q42869865 | ||
| Wolfgang A. Schulz | Q38326200 | ||
| P2093 | author name string | Ingo Schmitz | |
| Peter Albers | |||
| Christiane Hader | |||
| Tobias Lübke | |||
| P2860 | cites work | Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. | Q50922886 |
| A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. | Q51023679 | ||
| The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. | Q51032175 | ||
| FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. | Q52857898 | ||
| EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. | Q54391399 | ||
| The raf inhibitor paradox: unexpected consequences of targeted drugs. | Q54687011 | ||
| Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer | Q73311092 | ||
| Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment | Q80673261 | ||
| Stress-activated kinase pathway alteration is a frequent event in bladder cancer | Q39431237 | ||
| Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels | Q39556740 | ||
| The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib | Q39662629 | ||
| Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells | Q39677393 | ||
| Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma | Q39686307 | ||
| Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival | Q39761203 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. | Q40399567 | ||
| Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status | Q40588270 | ||
| The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier | Q42773975 | ||
| The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. | Q43195406 | ||
| Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05) | Q43718098 | ||
| Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors | Q43823457 | ||
| Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer | Q43844968 | ||
| Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines | Q44254660 | ||
| A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium | Q44951549 | ||
| Prevalence of KIT expression in human tumors | Q45150110 | ||
| Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation | Q45823928 | ||
| Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro | Q46476362 | ||
| Inhibition of death receptor signals by cellular FLIP | Q24316446 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| The role of c-FLIP in modulation of CD95-induced apoptosis | Q28293167 | ||
| Comprehensive molecular characterization of urothelial bladder carcinoma | Q28306864 | ||
| c-FLIP, a master anti-apoptotic regulator | Q28391119 | ||
| S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer | Q28477972 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Towards a knowledge-based Human Protein Atlas | Q29617987 | ||
| Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy | Q33572016 | ||
| Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006) | Q35607396 | ||
| The role of c-FLIP splice variants in urothelial tumours. | Q35657114 | ||
| Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. | Q35685794 | ||
| Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process | Q36057887 | ||
| Understanding urothelial carcinoma through cancer pathways | Q36430266 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation | Q36622253 | ||
| Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells | Q36742203 | ||
| Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation | Q36922674 | ||
| Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation | Q37172903 | ||
| Bladder cancer subtypes defined by genomic alterations | Q37278990 | ||
| Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group | Q37415341 | ||
| Targeting c-FLICE-like inhibitory protein (CFLAR) in cancer | Q38068479 | ||
| Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis. | Q38974167 | ||
| Targeted polytherapy in small cell sarcoma and its association with doxorubicin | Q38977714 | ||
| Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells. | Q39016475 | ||
| Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer | Q39031180 | ||
| Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells | Q39206134 | ||
| HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells. | Q39306394 | ||
| Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent | Q39431199 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 20500-20517 | |
| P577 | publication date | 2014-11-07 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Multiple mechanisms mediate resistance to sorafenib in urothelial cancer | |
| P478 | volume | 15 |
| Q38672966 | Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective? |
| Q36413738 | Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs |
| Q47212126 | Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. |
| Q55254546 | Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro. |
| Q89494101 | Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis |
| Q50182584 | Epigenetic Treatment Options in Urothelial Carcinoma |
| Q30489412 | Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. |
| Q26745320 | Modulation of Autophagy by Sorafenib: Effects on Treatment Response |
| Q64259068 | Precision medicine review: rare driver mutations and their biophysical classification |
| Q35998718 | Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer |
| Q38534167 | Targeting the VEGF pathway in metastatic bladder cancer |
| Q53787748 | [Resistance to anti-angiogenic therapy: a clinical and scientific current issue]. |
Search more.